Product logins

Find logins to all Clarivate products below.


Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)

Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi and Alecensa gained label expansions into the resectable early-stage NSCLC space. Additionally, Opdivo plus chemotherapy gained FDA approval for perioperative (neoadjuvant then adjuvant) use in this setting. The metastatic setting also saw new entrants to the space, with the approval of new biomarker-targeted agents: Bizengri for NRG1-mutated NSCLC, and Ensacove for NSCLC with ALK mutations. Additionally, Tecentriq Hybreza, a subcutaneous formulation of Tecentriq, was also approved in all adult indications approved for Tecentriq, including NSCLC. These approvals, against the backdrop of numerous existing agents in the NSCLC space, provide medical oncologists with an ever-increasing array of treatment options.

Questions answered

  • What are the treatment rates for NSCLC in the various settings and lines of therapy?
  • What are the rates of testing for different biomarkers, and what is the uptake of key biomarker-driven therapies?
  • How are new therapy entrants to the NSCLC market performing relative to existing therapies?
  • What do surveyed physicians consider the main drivers of and key obstacles to the uptake of select therapies?

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

  • Understand the treatment landscape for a disease and how physicians make prescribing decisions.
  • Evaluate the drivers and obstacles that influence treatment selection.
  • Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

Primary research: Survey of 102 U.S. medical oncologists in the United States fielded during February 24 to March 7, 2025.

Key drugs covered: Alecensa, Enhertu, Gavreto, Imfinzi, Imjudo, Keytruda, Krazati, Libtayo, Lumakras, Opdivo, Retevmo, Rybrevant, Tabrecta, Tagrisso, Tecentriq, Tecentriq Hybreza, Tepmetko, Yervoy.

Related Market Assessment Reports

Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie’s Rinvoq and Skyrizi, and UCB’s bimekizumab…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…